Phase 4
N=41
Loiasis Cross-reactive Antigenemia and Treatment-related Adverse Events
Loiasis
Bottom Line
View on ClinicalTrials.gov: NCT05085665 ↗Enrolled (actual)
41
Serious AEs
0.0%
Results posted
Sep 2022
Primary outcome: Primary: Cross-reactive Antigenemia — 12 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Ivermectin (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Washington University School of Medicine
- Primary completion
- Aug 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Cross-reactive Antigenemia |
12 | — |
Summary
This study seeks to determine which Loa loa antigens are released into circulation when infected individuals are treated with ivermectin.
Eligibility Criteria
Inclusion Criteria
- Loa loa blood microfilariae of between 5,000 - 18,000 per mL
Exclusion Criteria
- known allergy to ivermectin; severe comorbidities
Data sourced from ClinicalTrials.gov (NCT05085665). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.